5月6日 - ** 制药公司曼恩康德（MannKind）MNKD.O的股价在盘前交易中上涨8.4%，至3.10美元
** 该公司表示，将与United Therapeutics UTHR.O合作开发吸入型拉利奈帕（ralinepag），用于治疗肺动脉高压——一种会导致肺部血压升高的罕见疾病
** 公司表示，United Therapeutics将支付500万美元预付款；MannKind有资格获得最高3500万美元的里程碑付款以及10%的净销售额
** 联合治疗公司将负责主导生产及监管申报工作
** 称该吸入剂将首先在健康志愿者中进行测试，随后在肺动脉高压患者中进行测试
** 补充称，该药物虽尚未获批，但未来可能扩展至肺纤维化等其他肺部疾病
** 截至上一交易日收盘，该公司股价年内累计下跌约50%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.